Reference pricing changes to cost industry €650 million in Spain
This article was originally published in Scrip
Executive Summary
Not long after taking power, Spain's new government has signed into law changes to the reference pricing system, which will cost the pharmaceutical industry some €650 million. The new changes will exacerbate already tough market conditions and add to government measures introduced in 2011 aimed at shaving €2.4 billion off the drugs bill, says Farmaindustria, the association representing the R&D-based pharmaceutical industry.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.